logo BDSP

Base documentaire


Votre avis nous intéresse

Le réseau BDSP met en oeuvre un projet d'innovation et d'amélioration de ses services, dans le souci constant de proposer des contenus de qualité adaptés aux besoins des utilisateurs.

Identifier de nouvelles sources de financements est la condition nécessaire pour assurer la poursuite et la pérennité de cet outil unique qu'est la BDSP, tout en le faisant évoluer.

Pour définir un nouveau modèle économique, nous avons besoin de votre avis : merci de répondre à notre enquête (temps estimé : 5 minutes).

Participer maintenant
Participer plus tard J'ai déjà participé

  1. Hospital costs of treating haemophilic patients infected with HIV.

    Article - En anglais

    Objective 

    To calculate the costs of treating HIV-infected haemophilic patients.

    Design 

    Two-year retrospective study of hospital-based resource use and costs, from April 1991 to March 1993.

    Setting 

    Haemophilia Centre and Haemostasis Unit, Royal Free Hospital and School of Medicine, London, UK.

    Patients 

    Sixty patients infected with HIV between October 1979 and July 1985.

    Results 

    During the 2-year period a total of 1668 hospital visits were made by patients.

    The mean number of episodes per patient-year (PY) was 0.6 inpatient admissions, 11.5 outpatient visits and 1.8 day cases.

    The mean cost per PY was £32 528, with the majority of this spent on clotting factor concentrate products and haemophilia inpatient admissions (81%). A mean cost for HIV-related treatment of £6050 was estimated.

    The additional cost incurred in switching this group of haemophilic patients from intermediate-purity factor concentrate to high-purity products was £8614 per PY.

    Conclusions 

    CD4+count may be used as a marker of costs of HIV infection.

    The HIV-related cost estimates can be used for the planning of current and future hospital-based care in the National Health Service in the United Kingdom.

    The switch from intermediate-purity factor concentrate to high-purity products has increased the mean HIV-related cost per PY of treating haemophilic patients infected with HIV.

    Mots-clés Pascal : SIDA, Virose, Infection, Coût, Soin, Hémophilie, Traitement, Hôpital, Homme, Immunopathologie, Immunodéficit, Economie santé, Hémopathie, Coagulopathie, Maladie héréditaire

    Mots-clés Pascal anglais : AIDS, Viral disease, Infection, Costs, Care, Hemophilia, Treatment, Hospital, Human, Immunopathology, Immune deficiency, Health economy, Hemopathy, Coagulopathy, Genetic disease

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 95-0416086

    Code Inist : 002B06D01. Création : 01/03/1996.